Since the double festival, a number of pharmaceutical companies high-level "big change of blood"

Pharmaceutical Network Industry Dynamics: In the first three quarters of this year, executives of about 150 biopharmaceutical listed companies left.
And since the double section, the pharmaceutical industry personnel changes continue, a number of pharmaceutical companies at the top of the "big blood change", involving Liu medicine shares, crown biology, tablets , Beijing New Pharmaceuticals, Huatong Pharmaceuticals and other pharmaceutical companies.
industry analysis, behind a series of departures from pharmaceutical companies, is related to the overall development trend of the pharmaceutical industry, as well as the consistent evaluation in recent years, volume procurement and other industry policy changes.
: Senior management resigned october 13, Guangxi Liuzhou Pharmaceutical Co., Ltd. announced that the board of directors recently received the company's deputy general manager Mr. Qiu Zhima submitted a written resignation report.
Chu Zhimhong applied to resign as deputy general manager of the company for personal reasons.
the company's deputy general manager, he will no longer hold any position in the company, and his resignation will not affect the company's production and business activities.
: The securities representative resigned on October 13, Crown Bio announced that the company recently received the securities representative Ms. Chen Xi's resignation report.
Chen Xi applied to resign as the company's securities representative for personal reasons, and her resignation report is effective from the date of service to the company's board of directors, and she will no longer hold any position in the company after her resignation.
general manager of ST Kangmei resigned on October 13, ST Kangmei issued an announcement on the resignation of the general manager and the appointment of the general manager and deputy general manager.
the company's board of directors received a report on October 10, 2020 from Mr. Ma Xinggu, chairman and general manager of the company, who resigned as general manager of the company due to his work arrangements, according to the company's announcement.
, Mr. Ma Xinggu continued to serve as Chairman of the Company and as a member of the relevant Special Committee.
At the same time, in order to strengthen the management of the company, the company agreed to appoint Mr. Liu Guowei as the general manager of the company, agreed to appoint Mr. Miyaguibo as the company's deputy general manager, the term of office from the date of consideration and adoption of this board of directors to the end of the eighth board of directors.
: The directorOn October 10, the board of directors of the company announced that the board of directors of the company had recently received a written resignation report submitted by the director, Mr. Hong Dongming.
Hong Dongming applied to resign as a director of the company for work adjustment reasons.
: Vice President Zhou Lin resigned on the afternoon of October 9, Beijing New Pharmaceuticals announced that the company's board of directors received Zhou Lin's written resignation report on September 30, 2020.
for personal reasons, Zhou Lin applied to resign as vice president of the company, after which he will no longer hold any position in the company.
Huatong Pharmaceuticals: On the evening of October 8th, Huatong Pharmaceuticals announced the resignation of some of its chairman and some directors and supervisors, and announced the by-election of directors and supervisory candidates. according to the
announcement, Wang Luping applied to resign as chairman and convenor of the Strategy Committee for work adjustment reasons and will no longer hold any position in the company after resigning; The post of director and member of the audit committee shall be arranged separately after his resignation, Zhang Quan has applied to resign as chairman of the supervisory board for the reasons of work adjustment and will no longer hold any position of the company after resigning, and Yu Qunjian has applied to resign as supervisor for the reasons of work adjustment, and will still hold the post of head of the audit department of the company after resigning.